Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

8.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.3K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.5K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.5K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

Oncology reports·2020
Same author

Integrin β3 Deficiency Results in Hypertriglyceridemia via Disrupting LPL (Lipoprotein Lipase) Secretion.

Arteriosclerosis, thrombosis, and vascular biology·2020
Same author

Discovery of a Potent and Selective NF-κB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo.

Journal of medicinal chemistry·2020
Same author

Discovery of 8-Methyl-pyrrolo[1,2-<i>a</i>]pyrazin-1(2<i>H</i>)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors.

Journal of medicinal chemistry·2020
Same author

Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors.

Bioorganic & medicinal chemistry letters·2020
Same author

Compression of Cerebellar Functional Gradients in Schizophrenia.

Schizophrenia bulletin·2020
Same journal

BioMatics 1.0: A Wasserstein Distance Approach for Next-Generation Multiple Sequence Alignment.

Proteins·2026
Same journal

Engineered HSP90-MP65 Bivalent Fusion Antigen: A Novel Vaccine Candidate Against Invasive Candidiasis.

Proteins·2026
Same journal

Physics-Based Energy Functions for Computational Protein Design.

Proteins·2026
Same journal

Impact of Stabilizing Osmolytes on the Conformational Dynamics of Human and Rat Islet Amyloid Polypeptides.

Proteins·2026
Same journal

Stabilization of Bone Morphogenetic Protein-2 at Physiological pH: Contrasting Roles of CHAPS and Arginine in Aggregation Inhibition.

Proteins·2026
Same journal

Structural Insights Into the Function of Leishmania major Adenylosuccinate Lyase.

Proteins·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.4K

Cholesterol-β1 AR interaction versus cholesterol-β2 AR interaction.

Xiaohui Cang1, Linlin Yang, Jing Yang

  • 1Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; Institute of Genetics, College of Life Science, Zhejiang University, Hangzhou, Zhejiang, 310058, China.

Proteins
|November 23, 2013
PubMed
Summary
This summary is machine-generated.

Cholesterol molecules interact differently with beta-1 and beta-2 adrenergic receptors, revealing subtype-specific binding and new insights into cholesterol

Keywords:
G protein-coupled receptorcholesterol-binding sitemolecular dynamics simulationβ-adrenergic receptor

More Related Videos

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

5.6K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

8.6K

Related Experiment Videos

Last Updated: May 5, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.4K
Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

5.6K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

8.6K

Area of Science:

  • Molecular biology
  • Biophysics
  • Pharmacology

Background:

  • G protein-coupled receptors (GPCRs) are crucial drug targets.
  • Cholesterol modulates GPCR function and interaction.
  • Beta-1 and beta-2 adrenergic receptors are highly homologous GPCR subtypes.

Purpose of the Study:

  • To investigate subtype-specific cholesterol interactions with beta-1 and beta-2 adrenergic receptors.
  • To elucidate general determinants of cholesterol binding to GPCRs.
  • To reveal cholesterol binding pathways and sites within GPCRs.

Main Methods:

  • All-atom molecular dynamics simulations (8-µs).
  • Simulations of beta-1 and beta-2 adrenergic receptors embedded in a lipid bilayer.
  • Analysis of cholesterol molecule accumulation and binding modes.

Main Results:

  • Cholesterol molecules exhibit subtype-specific accumulation on beta-1 and beta-2 adrenergic receptors.
  • Key factors for cholesterol binding (concave surface, charged/aromatic residues) are important but not indispensable.
  • A cholesterol molecule's pathway into the consensus cholesterol motif (CCM) site was revealed, involving Trp4.50 side chain flipping.
  • An alternative cholesterol-binding site in the helix 6 extracellular region of class-A GPCRs was suggested.

Conclusions:

  • Cholesterol-GPCR interactions are subtype-specific, offering insights into physiological differences.
  • Diverse combinations of factors dictate varied cholesterol binding modes.
  • The study provides novel mechanistic insights into cholesterol binding to GPCRs, including a conserved binding pathway and an alternative binding site.